131 related articles for article (PubMed ID: 17723177)
21. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
Sasaki M; Sugimoto K; Isobe Y; Oshimi K
Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
[No Abstract] [Full Text] [Related]
22. Arsenic-induced APL differentiation in cerebrospinal fluid.
Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
[TBL] [Abstract][Full Text] [Related]
23. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
24. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Ma J
Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
[No Abstract] [Full Text] [Related]
25. Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: a single center experience.
Zhang L; Zhao H; Zhu X; Chen Y; Zou Y; Chen X
Pediatr Blood Cancer; 2008 Aug; 51(2):210-5. PubMed ID: 18428427
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapies for the treatment of leukemia.
Stull DM
Semin Oncol Nurs; 2003 May; 19(2):90-7. PubMed ID: 12830733
[TBL] [Abstract][Full Text] [Related]
27. Advancing the treatment of hematologic malignancies through the development of targeted interventions.
Tallman MS
Semin Hematol; 2002 Oct; 39(4 Suppl 3):1-5. PubMed ID: 12447845
[TBL] [Abstract][Full Text] [Related]
28. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
29. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
[TBL] [Abstract][Full Text] [Related]
30. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
31. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
32. Acute promyelocytic leukemia: a model of molecular target based therapy.
Zhou GB; Chen SJ; Chen Z
Hematology; 2005; 10 Suppl 1():270-80. PubMed ID: 16188687
[TBL] [Abstract][Full Text] [Related]
33. [Molecular diagnosis in hematologic malignancies].
Nara N
Rinsho Byori; 2002 Apr; 50(4):331-6. PubMed ID: 12014009
[TBL] [Abstract][Full Text] [Related]
34. Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia.
Menif S; Zarrouki S; Jeddi R; ben Alaya N; Ali ZB; Ben Abid H; Hdeiji S; Elloumi M; Khlif A; Meddeb B; Dellagi K
Pathol Biol (Paris); 2009 Jul; 57(5):388-91. PubMed ID: 18387753
[TBL] [Abstract][Full Text] [Related]
35. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
[TBL] [Abstract][Full Text] [Related]
36. Targeted therapy in chronic myeloid leukemia.
Jabbour E; Cortes JE; Ghanem H; O'Brien S; Kantarjian HM
Expert Rev Anticancer Ther; 2008 Jan; 8(1):99-110. PubMed ID: 18095887
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive review of acute promyelocytic leukemia in children.
Mantadakis E; Samonis G; Kalmanti M
Acta Haematol; 2008; 119(2):73-82. PubMed ID: 18285695
[TBL] [Abstract][Full Text] [Related]
38. Old, new drugs and new, new drugs for the new millennium.
Scheinberg DA
Curr Oncol Rep; 2000 Mar; 2(2):112-3. PubMed ID: 11122831
[No Abstract] [Full Text] [Related]
39. Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML).
Tsapas A; Vlachaki E; Sarigianni M; Klonizakis F; Paletas K
Leuk Res; 2008 Apr; 32(4):674-5. PubMed ID: 17920117
[No Abstract] [Full Text] [Related]
40. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase.
Li L; Wang J; Ye RD; Shi G; Jin H; Tang X; Yi J
J Cell Physiol; 2008 Nov; 217(2):486-93. PubMed ID: 18636556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
